Hemophilia is a sex-linked genetic disorder characterized by the deficiency or absence of one of the clotting proteins in plasma. Severe deficiency results in spontaneous bleeding into the joints and recurrent bleeding which, in turn, leads to hemophilic arthropathy, disability, and reduced quality of life. Currently, there is no known cure for hemophilia, so treatment goals include preventing bleeding, recognizing bleeding episodes, and providing prompt treatment and intervention to prevent complications.
- WEBCAST Utilizing CAR T Cells for Hematologic Malignancies in the Transplant Setting
- WEBCAST Updates on Hematologic Malignancies: New Targeted Conditioning Regimens
- BloodLine Presents: Updates on Current Treatment Options for Cytomegalovirus (CMV) in the Transplant Setting
- Blood and Marrow Transplantation Reviews: Examining Targeted Therapies for Hodgkin Lymphoma in the Post-Transplant Setting: Reason for Optimism
- Blood and Marrow Transplantation Reviews: Management of Multiple Myeloma: Using Emerging Therapies with ASCT